Evommune scraps eczema drug after trial miss, shares plunge

Evommune will discontinue development of its experimental skin-disease drug after it failed to meet the primary endpoint in a mid-stage clinical trial. Shares fell 24% in aftermarket trading, reflecting a material setback to the company’s pipeline and valuation.